• Latest News
    • Menstrual Health
    • Reproductive Health
    • Fertility
    • Pregnancy
    • Maternal Health
    • Menopause
    • Hormonal Health
    • Mental Health
    • Gynecological Health
    • Endometriosis
    • Chronic Conditions
    • Sexual Wellness
    • Heart Disease
    • Pelvic Health
    • Bone Health
    • Cancer
  • Newsletter
  • Become a Member
  • Jobs
  • Events

Femtech Investment Round-up (November 2022)

By Femtech Insider Investment Round-ups, News December 8, 2022
ShareTwitterFacebookPinterest-circled
  • Latest News
    • Menstrual Health
    • Reproductive Health
    • Fertility
    • Pregnancy
    • Maternal Health
    • Menopause
    • Hormonal Health
    • Mental Health
    • Gynecological Health
    • Endometriosis
    • Chronic Conditions
    • Sexual Wellness
    • Heart Disease
    • Pelvic Health
    • Bone Health
    • Cancer
  • Newsletter
  • Become a Member
  • Jobs
  • Events

To continue reading…

Become a premium member and get unlimited access to articles, weekly analysis, free access to out webinars and more:

Subscribe

Already a subscriber? Log in here.

You May Also Like

Gynecological Health, News, Partnership, Pharma February 18, 2026
Teijin Pharma and Aska Pharmaceutical Partner to Discover New Small-Molecule Drugs for Gynecological Diseases
Menstrual Health, News, Research January 10, 2022
Natural Cycles Releases the Results of a New Study on the Relationship Between COVID-19 Vaccines and the Menstrual Cycle
Recent Posts
  • Paterna Biosciences Announces It Has Grown Functional Human Sperm in the Lab
  • Vella Bioscience Launches Ebbtide, a CBD-Powered Vaginal Insert for Menstrual Cramping
  • Willow, Ema EQ, Clue, Oura, and Thrive Global Launch Women’s Health AI Consortium
  • PCOS Has Been Renamed to PMOS to Reflect Multisystem Disease
  • Mother Ventures Closes $10M Debut Fund Built Around the Mom-as-Consumer Market

About Femtech Insider

Advertise with us!

Become a Member!

Contact us

Privacy Policy // Terms of Use

Femtech Insider Ltd. © 2026. All rights reserved.